Ariad Pharmaceuticals Inc fka ARIA

[jbog]

Vidpok,

Sadly, many of the meaningful trials will run almost 5 years in follow-up so these will drag on for a long long time. I don't think Pona will move up the ladder until the 15mg/10mg dosing gains acceptance (Optic 2L), which is probably 7 years away. This trial goes head to head against Nilotinib in 2nd line.

Hopefully some of the Ph II trials in Lung, Glioblastoma, Biliary or Malignant Neoplasm's show some positive data in the meantime.


I don't expect Ariad to be around that long.